References
Bombardieri E, Ambrosini V, Aktolun C, et al; Oncology Committee of the EANM. 111In-pentetreotide scintigraphy procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010, 37: 1441–8.
Cascini GL, Cuccurullo V, Mansi L. The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology. Q J Nucl Med Mol Imaging 2010, 54: 24–36.
Gibril F, Reynolds JC, Chen CC, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999, 40: 539–53.
Klecker RJ, Cioc AM, Pozderac RV. Positive In-111 pentetreotide scintigraphy: pulmonary hamartoma. Clin Nucl Med 2001, 26: 251–2.
Servaes S, El-Haddad G, Zhuang H. Intense octreotide activity in a thrombus. Clin Nucl Med 2008, 33: 140–1.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Minutoli, F., Herberg, A., Sindoni, A. et al. A potentially misleading finding at somatostatin receptor scintigraphy: Focal pulmonary areas of intense accumulation without computed tomography-detectable lung lesions. J Endocrinol Invest 35, 708–709 (2012). https://doi.org/10.1007/BF03345801
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345801